Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year
You may also be interested in...
South Korea’s Celltrion Optimistic On June EMA Approval For Remicade Biosimilar
Johnson & Johnson may soon face more competition to Remicade from Celltrion’s biosimilar Remsima, with the South Korean company more optimistic about EMA approval following a positive response at one of the world’s largest rheumatology congresses.
Celltrion Files For Korea Approval Of Herceptin Biosimilar
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.
Korea’s Celltrion Seeks New Trial Design For Rituxan Biosimilar Phase III
Celltrion says it will launch Phase III trials in the second half of 2013 with a new design, after completing a Phase I trial this month.